Prevention and pharmacovigilance: What should we do, what can we do?

Drug Safety

Volumn 35, Issue 2, 2012, Pages 87-90

  Edwards, I Ralph ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Ethics; Pharmacovigilance; Risk management

Indexed keywords

CEPHALOSPORIN; PENICILLIN G;

DRUG SURVEILLANCE PROGRAM; EDITORIAL; HUMAN; MEDICAL ETHICS; PRIORITY JOURNAL; PROPHYLAXIS; RISK MANAGEMENT; TURKEY (REPUBLIC);

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MEDICATION ERRORS; PHARMACOVIGILANCE; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 84855830699     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11630510-000000000-00000     Document Type: Editorial

References (4)

1. Mease M. Measuring REMS effectiveness: time for a program overhaul? [abstract]. Drug Saf 2011; 34 (10): 887
2. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan-Feb; 12 (1): 17-29 (Pubitemid 36192946)
3. Ferner RE, Aronson JK. Preventability of drug-related harms-part I: a systematic review. Drug Saf 2010Nov 1; 33 (11): 985-94
4. Aronson JK, Ferner RE. Preventability of drug-related harms-part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010 Nov 1; 33 (11): 995-1002